ATRi Transition Rollover Study
About the study
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Participants ongoing treatment in Vertex study VX13-970-002.
- Participant must be able to understand and provide written informed consent.
- Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
EXCLUSION CRITERIA
Exclusion Criteria:
* Participants experiencing disease progression or unacceptable toxicity at the time of transition into the this study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Advanced Stage Solid Tumors
Phase
PHASE1
Participants Needed
1
Est. Completion Date
Jan 26, 2024
Treatment Type
INTERVENTIONAL
Sponsor
Merck KGaA, Darmstadt, Germany
ClinicalTrials.gov NCT Identifier
NCT03309150
Study Number
MS201923-0007
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?